Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Processa Pharmaceuticals Inc

PCSA ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: N/A

Last Close

$2.18

▲ +0.46%

Market Cap $6.09M · Vol 6.21K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$6.09M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

49.58

Momentum

Beta

0.95

vs Market

52W High

$14.00

84.43% below

52W Low

$1.75

24.57% above

Volume

6.21K

Avg 59.76K

P/B

1.33

Price-to-book

ROE

N/A

Return on equity

Free Float

85.18%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Processa Pharmaceuticals Inc (PCSA) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does PCSA pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.81%

-16.15%

-17.74%

+3.81%

YTD

-24.31%

-60.90%

-98.62%

-99.93%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-13,563,830.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-245.66% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.33
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	2.79M

Technical Indicators

50-Day SMA	$2.22
200-Day SMA	$3.22
RSI (14)	49.58
Beta	0.95
52-Week High	$14.00
52-Week Low	$1.75

Volume Today	6.21K
Avg Daily Volume (30D)	59.76K
Relative Volume	0.10x
Volatility (10D)	69.75
Volatility (30D)	153.69
Free Float	85.18%

Analyst Consensus

N/A

Current Price $2.18

Mean Target $25.00

52W Low$1.75 52W High$14.00

Current

Target

$1.75 $14.00

Current Analyst target

+1,046.79% upside potential · 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG003MN60F5

ISINUS74275C4033

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd +3.29% ARGX.BR argenx SE +1.74% ARGX argenx SE +0.83% 2269.HK WuXi Biologics (Cayman) Inc +7.41% INSM Insmed Inc -0.07%

Company Profile

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of Next Generation Cancer therapy (NGC) small molecules. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri) and two non-oncology drug assets are PCS12852, and PCS499. NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil.PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38). PCS12852 is a specific and potent 5HT4 agonist that is in Phase IIB and is a potential treatment for diabetic gastroparesis patients. PCS499 is a drug that can be used to treat unmet medical needs and conditions caused by multiple pathophysiological changes.